Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Cytokinetics, Incorporated (CYTK)

63.64 +2.02 (+3.28%)
As of 3:02:09 PM EDT. Market Open.
Trade CYTK on Coinbase
Chart Range Bar
Loading chart for CYTK
  • Previous Close 61.62
  • Open 61.62
  • Bid 45.67 x 200
  • Ask 78.87 x 200
  • Day's Range 60.99 - 64.01
  • 52 Week Range 54.30 - 88.31
  • Volume 1,131,679
  • Avg. Volume 1,957,812
  • Market Cap (intraday) 8.847B
  • Beta (5Y Monthly) 0.41
  • PE Ratio (TTM) --
  • EPS (TTM) -7.22
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 109.95

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

www.cytokinetics.com

673

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/14/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CYTK
0.16%
S&P 500 (^GSPC)
12.50%

1-Year Return

CYTK
4.28%
S&P 500 (^GSPC)
15.91%

3-Year Return

CYTK
86.03%
S&P 500 (^GSPC)
77.95%

5-Year Return

CYTK
66.90%
S&P 500 (^GSPC)
73.52%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 28.62M
Earnings -198.76M
Profit Margin -694.39%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-300M
-200M
-100M
0
-15000.0%
-10000.0%
-5000.0%

Analyst Insights

View More

Analyst Price Targets

85.00
109.95 Average
63.64 Current
146.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/8/2026
Analyst RBC Capital
Rating Action Maintains
Rating Outperform
Price Action Raises
Price Target 112 -> 113

Statistics

View More

Valuation Measures

Annual
As of 9/17/2026
  • Market Cap

    9.15B

  • Enterprise Value

    9.26B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    128.60

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    145.20

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -28.09%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    67.67M

  • Net Income Avi to Common (ttm)

    -894M

  • Diluted EPS (ttm)

    -7.22

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.17B

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -397.41M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

63.64 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Rating decreased to a SELL

    CYTOKINETICS INC has an Investment Rating of SELL; a target price of $52.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.

  • Lowering target price to $62.00

    CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $62.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.

  • Lowering target price to $64.00

    CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $64.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.

  • Lowering target price to $66.00

    CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $66.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: